Hepatocellular CarcinomaNCT07235410
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
An observational study of Hepatocellular Carcinoma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment. However, patients often respond differently to TACE, and it is difficult to predict who will benefit most. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 1 Nov 2025to 1 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: hepatocellular carcinoma
Who may be able to join
- Patients diagnosed with "Hepatocellular Carcinoma" from January 1, 2018 to May 31, 2024;
- Age > 18 years old.
Who cannot join
- Poor image quality;
- Loss of follow-up;
- Presence of another type of malignant tumor other than liver cancer;
- Incomplete medical records.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022
Yi Li, +8617364176403, evelyn1224@foxmail.com
About this study
Official title: Deep Learning-Based Multidimensional Body Composition Mapping for Predicting Clinical Outcomes in Hepatocellular Carcinoma Patients Undergoing TACE
Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment. However, patients often respond differently to TACE, and it is difficult to predict who will benefit most. This study uses deep learning to automatically analyze routine CT images taken before TACE. By measuring body composition features, such as the size and condition of different abdominal organs and tissues, we aim to better understand patients' overall health status and treatment tolerance. The goal is to develop a prediction model that can help doctors estimate survival and treatment outcomes more accurately. This may assist in making more personalized treatment decisions and improving patient care.
- Conditions
- Hepatocellular Carcinoma
- Medical subject headings
- Carcinoma, Hepatocellular
What is being measured
The primary outcome is the main question the study is designed to answer.
OS
Measured: After the TACE procedure until May 1, 2025
Secondary outcomes (1)
PFS
Measured: After the TACE procedure until May 1, 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2025
- Study start1 Nov 2025
- Primary completion31 Dec 2025 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lian Yang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07235410
- Sponsor's protocol ID
- [2025](1186)
- Status last verified
- Nov 2025
- First submitted
- 14 Nov 2025
- Last updated
- 19 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Deep Learning-Based Multidimensional Body Composition Mapping for Predicting Clinical Outcomes in Hepatocellular Carcinoma Patients Undergoing TACE
- ClinicalTrials.gov ID
- NCT07235410
- Acronym / sponsor ID
- [2025](1186)
- Conditions
- Hepatocellular Carcinoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 19 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment. However, patients often respond differently to TACE, and it is difficult to predict who will benefit most. This study uses deep learning to automatically analyze routine CT images taken before TACE. By measuring body composition features, such as the size and condition of different abdominal organs and tissues, we aim to better understand patients' overall health status and treatment tolerance. The goal is to develop a prediction model that can help doctors estimate survival and treatment outcomes more accurately. This may assist in making more personalized treatment decisions and improving patient care.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- hepatocellular carcinoma
Key inclusion criteria (2 listed)
- Patients diagnosed with "Hepatocellular Carcinoma" from January 1, 2018 to May 31, 2024;
- Age > 18 years old.
Key exclusion criteria (4 listed)
- Poor image quality;
- Loss of follow-up;
- Presence of another type of malignant tumor other than liver cancer;
- Incomplete medical records.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
OS
Time frame: After the TACE procedure until May 1, 2025
1 secondary outcome
PFS
Time frame: After the TACE procedure until May 1, 2025
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Hepatocellular Carcinoma
Not yet recruitingPhase 3
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Not yet recruiting
Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-Resectable
RecruitingPhase 2
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma, HCC
Active, not recruitingPhase 2
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatocellular Carcinoma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yuanyuan Chu (+8602785726375, whunionlunli@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
OS (time frame: After the TACE procedure until May 1, 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2025.